Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus Anlotinib in ED-SCLC
NCT04055792Phase 2Completed
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2019
- Primary completion
- May 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, anlotinib in small cell lung cancer (SCLC), sponsored by Henan Cancer Hospital. Started Sep 2019; status: completed.
02
Drugs
sintilimabanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04055792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04055792.